Clinical Trial Update: Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age [Phase 2]

View source ↗

Summary

Phase 2 immunogenicity and safety study of GSK's GSK2202083A vaccine in healthy infants aged 2, 3, and 4 months completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acellular Pertussis
• Diphtheria
• Haemophilus Influenzae Type
• Hepatitis B
• Poliomyelitis
• Tetanus

Drugs mentioned

• GSK2202083A vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tetanus, Diphtheria | Phase 2 | Status: COMPLETED | Results posted: 2017-04-14